Key Highlights

● INDP closed at $2.38 on Friday, October 2, 2026, a gain of 12.26% on the session.

● No clinical-trial result, regulatory decision, financing, Partnership or analyst action could be tied to the session.

● Small-cap biotech shares rest on uncertain clinical and regulatory outcomes, so they can swing sharply on sentiment or order flow.

● A double-digit move in a stock priced near two dollars fits that pattern, and such advances can reverse abruptly.

Indaptus Therapeutics (NASDAQ:INDP), a clinical-stage biotechnology company, was among Friday’s sharp gainers, closing at $2.38, up 12.26% on October 2, 2026. The move came on a day of broadly rising risk appetite across US equities, and no company-specific announcement was found.

No Clinical or Financing Event Behind INDP’s Gain

No company-specific announcement was found for Indaptus Therapeutics on October 2. There was no confirmed clinical-trial result, regulatory decision, financing, partnership, or analyst action tied to the session. In the absence of such news, the gain reflects the speculative, low-float momentum dynamics that characterize small development-stage biotechnology stocks, combined with the day’s favorable market backdrop.

Why Small-Cap Biotech Swings Sharply

Small-cap biotechnology shares are among the most volatile in the market. With much of their value resting on the uncertain outcomes of future clinical and regulatory events, and with relatively few freely traded shares in many cases, they can swing sharply on shifts in sentiment or order flow that have no connection to fresh company information. A double-digit percentage move in a session, in a stock priced near two dollars, is consistent with that pattern. Such advances are characteristically fragile and can reverse just as abruptly, particularly when they are not underpinned by a verified catalyst.

A Supportive Macro Setting

The broader market offered a supportive setting. A much weaker-than-expected September jobs report drove US stocks higher: nonfarm payrolls rose just 29,000 against consensus expectations near 84,000, and the Unemployment rate ticked up to 4.2%. The soft data prompted investors to pare back bets on further Federal Reserve tightening, easing Treasury yields from recent multiyear highs.

Lower yields are generally helpful for speculative, long-duration growth assets, a category that includes development-stage biotech, because such companies are valued on cash flows expected far in the future and become relatively more attractive when discount rates ease. The S&P 500 finished at 7,726.80, up 0.71%, at new highs, the Nasdaq-100 closed at an all-time high of 30,820.80, up 0.98%, and the Dow Jones Industrial Average rose 0.48% to 51,197.18, with gainers outpacing decliners.

In an environment where investors are more willing to embrace risk, the most speculative corners of the market, including early-stage biotech, can draw disproportionate interest and see outsized moves. No clinical, regulatory or financial event was confirmed for Indaptus Therapeutics on October 2, and the move reads as a function of trading dynamics and the macro backdrop.

The session was not uniformly positive. Hard-disk-drive makers Seagate (NASDAQ:STX) and Western Digital (NASDAQ:WDC) fell sharply after Toshiba announced plans to double its storage production capacity, stoking oversupply fears, a reminder that subsector-specific forces continued to operate beneath the broad rally. In commodities, Crude Oil dropped roughly 3.9% on the session while gold held firm near all-time highs, consistent with the rotation toward rate-sensitive Assets that eased yields encourage.

Speculative Low-Float Biotech Trading

INDP’s gain lacked a confirmed company catalyst and carried the hallmarks of speculative, low-float biotech trading. The same Volatility that produces a sharp rise can drive an equally sharp decline.